Osteoporosis: Whom, when and how to treat?
Authors:
J. Štěpán
Authors‘ workplace:
Revmatologický ústav, Praha a 1. LF UK, Praha
Published in:
Čas. Lék. čes. 2009; 148: 25-33
Category:
Review Article
Overview
Osteoporosis is a chronic disease of mass appearance and should be defined as a disease of decreased bone strength rather than a disease of decreased bone mass. Osteoporosis related fractures are of particular interest due to their high burden on the individual and society and also their importance as a target of pharmacological intervention. Bone mineral measurement (BMD), which is an established tool to diagnose osteoporosis (W.H.O., 1994) is not sufficient as a tool for treatment decisions. Currently, assessment of quality of bone is costly, technically demanding and/or invasive. In clinical practice, the W.H.O. recommendation (2007) enables a more advantageous assessment of individual absolute risk of fracture based on BMD and clinical risk factors independent of BMD (sex, age, prevalent fracture, parent fractured hip, use of glucocorticoids, rheumatoid arthritis, secondary osteoporosis, smoking, and excessive alcohol intake). Modern regimens of anticatabolic (antiresorption) therapies not only maintain bone microarchitecture but enable a sufficient bone renewal in majority of patients. However, even with anticatabolic treatments, aging is associated with decrease in new bone formation and mechanical competence of bone. Performance of bone osteoblasts and osteocytes, bone volume and quality and architecture of bone is improved in patients treated with bone anabolic agents. Teriparatide treatment considerably reduces risk of vertebral and nonvertebral fracture, back pain and different aspects of quality of life. However, use of the bone anabolic drugs is limited to 18-24 months. To prevent subsequent increase in risk of fracture, sequential treatments with anabolic and anti-catabolic drugs offer benefits needed for the long-term compliance. In conclusion, selection of drugs with the highest antifracture efficacy should be guided by the underlying mechanisms of osteoporosis, and by expectations of the treatment (safety and efficacy). Anti-catabolic drugs are most appropriate in patients with high bone turnover. Anabolic treatment is indicated in patients with low bone formation in the elderly, in glucocorticoid induced osteoporosis, and where preservation of bone mass and bone architecture by anti-catabolic drugs is not sufficient to efficiently reduce high absolute risk of fracture.
Key words:
aminobisphosphonate, fracture, osteoporosis, risk assessment, teriparatide.
Sources
1. NIH Consensus Development Panel on Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–795.
2. Štěpán JJ, Havelka S, Kamberská Z, Bernátová M. Epidemiologie der Osteoporose in der Tschechischen Republik. J Mineralstoffwechsel 2002; 9: 7–13.
3. Kanis JA, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 2000; 11: 669–674.
4. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int 2006; 17: 1726–1733.
5. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15: 721–739.
6. Kim HJ, Zhao H, Kitaura H, et al. Glucocorticoids suppress bone formation via the osteoclast. J Clin Invest 2006; 116: 2152–2160.
7. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004; 19: 893–899.
8. van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000; 39: 1383–1389.
9. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest,1998; 102: 274–282.
10. Eghbali-Fatourechi G, Khosla S, Sanyal A, et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 2003; 111: 1221–1230.
11. Sun L, Peng Y, Sharrow AC, et al. FSH directly regulates bone mass. Cell 2006; 125: 247–260.
12. Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86: 3555–3561.
13. Cauley JA, Danielson ME, Boudreau RM, et al. Inflammatory markers and incident fracture risk in older men and women: the health aging and body composition study. J Bone Miner Res 2007; 22: 1088–1095.
14. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005; 20: 177–184.
15. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 2007; 10: 102–110.
16. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner. Res, 1993; 8: 1137–1148.
17. World Health Organisation: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. Geneva: WHO 1994.
18. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254–1259.
19. Kanis JA, Gluer CC. An update on the diagnosis and assessment of osteoporosis with densitometry. Committee of Scientific Advisors, International Osteoporosis Foundation. Osteoporos. Int 2000; 11: 192–202.
20. Chapuy MC, Meunier PJ. Prevention of secondary hyperparathyroidism and hip fracture in elderly women with calcium and vitamin D3 supplements. Osteoporos. Int 1996; 6 (Suppl 3): 60–63.
21. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone, 2004; 34: 736–746.
22. Writing Group for the Women’s Health Initiative I: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333.
23. Richman S, Edusa V, Fadiel A, Naftolin, F. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. Menopause 2006; 13: 148–155.
24. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637–645.
25. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005; 20: 1514–1524.
26. Chesnut, Ch. 3rd, Azria M, Silverman S, et al. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos. Int 2008; 19: 479–491.
27. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int 2008; 19: 733–759.
28. Boivin G, Chavassieux P, Meunier P. Histomorphometry of bone. Effects of different treatments on bone remodeling and mineralization. Osteologicky Bull 2002; 7: 5–9.
29. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90: 1294–1301.
30. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007; 41: 122–128.
31. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–1822.
32. Rosa J. Doporučené postupy pro diagnostiku a terapii postemnopauzální osteoporózy II. Osteologický Bull 2007; 12: 74–81.
33. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008; 58: 1687–1695.
34. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434–1441.
35. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1–34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997; 138: 4607–4612.
36. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007; 146: 326–339.
37. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 5212–5220.
38. Boonen S, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54: 782–789.
39. Lindsay R, Miller P, Pohl G, et al. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 2009; 20, v tisku (Epub 2008/10/17).
40. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028–2039.
41. Siris ES, Miller PD, Barrett Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001; 286: 2815–2822.
42. WHO: Assessment of osteoporosis at the primary health care level. Report of a WHO Study Group. Sheffield: University of Sheffield Medical School UK 2007.
43. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007; 18: 1033–1046.
44. Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX – assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19: 1395–1408.
45. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 2008; 19: 437–447.
46. Felsenberg D, Silman AJ, Lunt M, et al. Incidence of vertebral fractures in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17: 716–724.
47. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339: 292–299.
48. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42: 2309–2318.
49. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid–induced osteoporosis in men and women: a randomized trial. European Corticosteroid–Induced Osteoporosis Treatment Study. J Bone Miner Res 2000; 15: 1006–1013.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
Most read in this issue
- Fatty acids – 1. Occurrence and biological significance
- Osteoporosis: Whom, when and how to treat?
- Coffee, its legend, history, and influence on human health
- Nitric oxide in patients with obesity and metabolic syndrome